Literature DB >> 2119789

The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections.

M Wachsman1, L Aurelian, J W Burnett.   

Abstract

In an open study, continuous oral therapy with cyclooxygenase inhibitors (ibuprofen or indomethacin) reduced the incidence and frequency of recurrent eruptions in nine of 16 patients with herpes simplex virus infection. Retrospective analysis of seven cases indicated that natural killer cell enhancement assays might allow us to predict the clinical outcome of such treatment.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2119789     DOI： 10.1111/j.1365-2133.1990.tb06298.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  10 in total

1.  COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.

Authors:  Tonia L Symensma; DeeAnn Martinez-Guzman; Qingmei Jia; Eric Bortz; Ting-Ting Wu; Nandini Rudra-Ganguly; Steve Cole; Harvey Herschman; Ren Sun
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Cyclooxygenase-1 and -2 are expressed by human T cells.

Authors:  J L Pablos; B Santiago; P E Carreira; M Galindo; J J Gomez-Reino
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression.

Authors:  Neelam Sharma-Walia; Hari Raghu; Sathish Sadagopan; Ramu Sivakumar; Mohanan Valiya Veettil; Pramod P Naranatt; Marilyn M Smith; Bala Chandran
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 4.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

5.  A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.

Authors:  Manish Kumar; James M Hill; Christian Clement; Emily D Varnell; Hilary W Thompson; Herbert E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

6.  Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus.

Authors:  Jörg Schröer; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

7.  Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus.

Authors:  Neelanjana Ray; Margaret E Bisher; L W Enquist
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia.

Authors:  William L Pridgen; Carol Duffy; Judy F Gendreau; R Michael Gendreau
Journal:  J Pain Res       Date:  2017-02-22       Impact factor: 3.133

9.  A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis.

Authors:  Christoph F Gfeller; Rita Wanser; Harish Mahalingam; David J Moore; Xuying Wang; Connie B Lin; Gilbert Shanga; Gary Grove; Anthony V Rawlings
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-03-22

10.  Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells.

Authors:  Jun-Ting Liou; Zih-Yan Chen; Ling-Jun Ho; Shih-Ping Yang; Deh-Ming Chang; Chun-Chin Liang; Jenn-Haung Lai
Journal:  Eur J Pharmacol       Date:  2008-05-06       Impact factor: 4.432
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.